Equities

Flerie AB

Flerie AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)46.18
  • Today's Change0.88 / 1.94%
  • Shares traded27.07k
  • 1 Year change+111.83%
  • Beta-0.0060
Data delayed at least 15 minutes, as of Nov 25 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments294345428
Total Receivables, Net000
Total Inventory------
Prepaid expenses0.740.2912
Other current assets, total1.612.132.40
Total current assets297347443
Property, plant & equipment, net2.773.992.16
Goodwill, net------
Intangibles, net------
Long term investments0.000.000.00
Note receivable - long term------
Other long term assets------
Total assets299351445
LIABILITIES
Accounts payable6.746.564.50
Accrued expenses506.863.57
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.700.630.81
Other current liabilities, total1.070.691.69
Total current liabilities591511
Total long term debt1.602.630.48
Total debt2.303.251.28
Deferred income tax------
Minority interest------
Other liabilities, total00.020.12
Total liabilities611711
SHAREHOLDERS EQUITY
Common stock111111
Additional paid-in capital864864863
Retained earnings (accumulated deficit)(636)(540)(440)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00----
Total equity239334434
Total liabilities & shareholders' equity299351445
Total common shares outstanding5.335.335.33
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.